We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 25% below its sector, cheaper than its peers on earnings.
Krka, d. d. is a leading generic pharmaceutical enterprise primarily involved in the research, production, promotion, and sale of various pharmaceutical goods. Its market presence spans Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and numerous other international territories. The company's offerings are categorized into prescription medications, over-the-counter products, and veterinary health solutions. Its prescription drug pipeline targets a broad spectrum of medical conditions, including cardiovascular disorders, gastrointestinal issues, central nervous system ailments, pain management, anti-infective treatments, conditions affecting blood and blood-forming organs, urological problems, diabetes, and oncology. The array of non-prescription items includes products for oral and throat care, cough and cold remedies, analgesics, nasal preparations, vitamin and mineral supplements, products designed to enhance cerebral and peripheral circulation, digestive aids, and various general healthcare products. Furthermore, Krka supplies animal health products such as anti-infectives, antiparasitics, and other specialized formulations for both livestock and companion animals. Beyond its pharmaceutical operations, the company also provides health resort and tourist services. Krka, d. d. was established in 1954 and has its corporate headquarters in Novo Mesto, Slovenia.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save KRK.WA and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
